Honeysuckle active compound as well as preparation method and application thereof
By extracting and separating active compounds from *Hylocereus undatus*, the safety and stability issues of skin whitening products have been resolved, achieving effective tyrosinase inhibition and antioxidant effects. At the same time, it provides safe α-glucosidase inhibition in hypoglycemic drugs, overcoming the shortcomings of existing technologies.
Patent Information
- Application Number
- CN202411025416.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
AI Technical Summary
Existing skin-whitening substances pose carcinogenic risks and environmental factors can affect their whitening effects. Blood sugar-lowering drugs can cause gastrointestinal discomfort and malabsorption. There is a lack of safe and effective alpha-glucosidase inhibitors on the market.
Using *Hylocereus undatus* as raw material, an active compound with tyrosinase inhibitory, antioxidant, and α-glucosidase inhibitory effects was prepared through steps such as soaking in anhydrous ethanol, concentration under reduced pressure, extraction with petroleum ether and ethyl acetate, and separation by silica gel column chromatography.
The prepared active compounds from *Hylocereus undatus* effectively inhibit tyrosinase and scavenge free radicals in whitening products, and safely inhibit α-glucosidase in hypoglycemic drugs, solving the safety and stability problems of existing products and providing good whitening and hypoglycemic effects.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of plant extracts, and particularly relates to a Lachnophora sphaerocephala active compound and a preparation method and application thereof. Background Art
[0002] Spiradiclis villosa belongs to the genus Spiradiclis, Rubiaceae, and is a perennial herb endemic to my country. It is mainly distributed in Guangxi and generally grows on rocks under forests.
[0003] So far, no research reports on the secondary metabolites and biological activities of Lachnophora have been found. The main problem to be solved in whitening is melanin deposition. Tyrosinase is the main rate-limiting enzyme in the formation of melanin. In this process, oxygen free radicals play a role in promoting the formation of melanin. Therefore, inhibiting tyrosinase and scavenging free radicals are two key ways to whiten the skin. At present, most whitening substances, such as hydroquinone and vitamin C, achieve whitening effects by inhibiting tyrosinase or antioxidant activity. Although hydroquinone has obvious whitening effects, it is prohibited for use due to carcinogenic risks. Vitamin C is easily affected by factors such as light, heat, humidity and pH value during the preparation process and changes color. Hypoglycemia mainly inhibits the activity of α-glucosidase, which is an enzyme in the body responsible for decomposing complex carbohydrates. It specifically hydrolyzes α-glucosidic bonds to release glucose and plays a key role in carbohydrate metabolism and glycoprotein processing. Delaying the production and absorption of glucose, lowering postprandial blood sugar and reducing the stimulation of high blood sugar oxidative stress on organs such as the pancreas, protecting pancreatic function, and achieving the effect of preventing and treating diabetes.
[0004] At present, α-glucosidase inhibitors are widely used in clinical practice to reduce postprandial hyperglycemia. The best-performing ones are acarbose and miglitol, which are the first-choice drugs for type 2 diabetes and adjuvant drugs for insulin treatment of type 1 diabetes. However, both drugs can cause gastrointestinal discomfort in patients. Therefore, finding more efficient and safe α-glucosidase inhibitors in food or medicinal plants is a hot topic in type 2 diabetes intervention research. There is an urgent need for the development of natural raw materials. At present, there are no reports on the use of tricholoma in whitening and antioxidant products and blood sugar-lowering products on the market. Summary of the invention
[0005] The purpose of the present invention is to provide an active compound of Lachnospira spp. and a preparation method and application thereof. The active compound of Lachnospira spp. has good whitening, anti-oxidation and blood sugar lowering effects.
[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0007] A method for preparing an active compound of Lachnophora sphaerocephala, comprising the following steps:
[0008] S1. Naturally air-drying and crushing the sample of Lachnophora sphaerocephala to obtain powder;
[0009] S2, soaking the powder obtained in step S1 in anhydrous ethanol, and concentrating under reduced pressure to obtain an ethanol extract;
[0010] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0011] S4. The petroleum ether extract or ethyl acetate extract obtained in step S3 is separated on a 300-400 mesh silica gel chromatography column and eluted with a petroleum ether-ethyl acetate mobile phase to obtain multiple components, which are further separated and purified to obtain active compounds through an elution procedure.
[0012] Preferably, in step S2, the volume ratio of anhydrous ethanol to powder is 1:1, and the soaking is performed 3 times, each time for 7 days.
[0013] Preferably, in step S2, the temperature of reduced pressure concentration is 37°C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, and the condensed water temperature is 5°C.
[0014] Preferably, in step S4, the chromatography column used in the separation and purification is one or both of a 300-400 mesh silica gel chromatography column or a Sephadex LH-20 gel column chromatography column.
[0015] Preferably, in step S4, the mobile phase in the elution procedure is one or more of petroleum ether-ethyl acetate, dichloromethane-methanol, and petroleum ether-dichloromethane-methanol.
[0016] Preferably, in step S4, the petroleum ether extract is chromatographed on a 300-400 mesh silica gel column, and petroleum ether-ethyl acetate mobile phase is used for gradient elution at a ratio of 50:1, 20:1, 10:1, and 1:1 to obtain 11 components (Fr.P1-Fr.P11).
[0017] Component Fr.P3 was separated on a 300-400 mesh silica gel column, and eluted with petroleum ether-ethyl acetate mobile phase at a ratio of 70:1 to obtain four subcomponents Fr.P3A-Fr.P3D. Subcomponent Fr.P3C was chromatographed on a Sephadex LH-20 gel column, and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain the active compound.
[0018] Component Fr.P5 was separated on a 300-400 mesh silica gel column, and eluted with petroleum ether-ethyl acetate mobile phase at a ratio of 25:1 to obtain five subcomponents Fr.P5A-Fr.P5E. Subcomponent Fr.P5D was chromatographed on a Sephadex LH-20 gel column, and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain the active compound.
[0019] Component Fr.P7 was chromatographed on a Sephadex LH-20 gel column, eluted with a mobile phase of petroleum ether-dichloromethane-methanol at a ratio of 2:1:1, and obtained two subcomponents Fr.P7A-Fr.P7B. Subcomponent Fr.P7B was chromatographed on a 300-400 mesh silica gel column, eluted with a mobile phase of dichloromethane-methanol at a ratio of 300:1, and obtained five subcomponents Fr.P7B1-Fr.P7B5. Subcomponent Fr.P7B2 was chromatographed on a 300-400 mesh silica gel column, eluted with a mobile phase of dichloromethane-methanol at a ratio of 800:1, and obtained the active compound.
[0020] Preferably, the ethyl acetate extract is separated on a 300-400 mesh silica gel chromatography column, and eluted with a petroleum ether-ethyl acetate mobile phase at a gradient ratio of 5:1 and 1:1 to obtain 11 components (Fr.E1-Fr.E11).
[0021] Component Fr.E4 was separated on a 300-400 mesh silica gel chromatography column and eluted with dichloromethane-methanol mobile phase at a ratio of 150:1 to obtain two sub-components Fr.E4A-Fr.E4B. Component Fr.E4B was chromatographed on a Sephadex LH-20 gel column and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain the active compound.
[0022] Component Fr.E5 was separated on a 300-400 mesh silica gel column, and the mobile phase of petroleum ether-ethyl acetate was eluted at a gradient of 3:1 and 1:1 to obtain three sub-components Fr.E5A-Fr.E5C. Component Fr.E5C was separated on a 300-400 mesh silica gel column, and the mobile phase of petroleum ether-ethyl acetate was eluted at a ratio of 4:1 to obtain three sub-components Fr.E5C1-Fr.E5C3. Sub-component Fr.E5C3 was chromatographed on a Sephadex LH-20 gel column, and the mobile phase of petroleum ether-dichloromethane-methanol was eluted at a ratio of 2:1:1 to obtain two sub-components Fr.E5C3A-Fr.E5C3B. Sub-component Fr.E5C3B was separated on a 300-400 mesh silica gel column, and the mobile phase of dichloromethane-methanol was eluted at a ratio of 80:1 to obtain the active compound.
[0023] The above-mentioned proportions of mobile phase are all volume ratios.
[0024] The present invention also provides a method for preparing the active compound of Lachnospira spp. to prepare the obtained active compound of Lachnospira spp.
[0025] Preferably, the structure of the active compound of Lachnophora sphaerocephala includes:
[0026]
[0027] The present invention also provides the Lachnospira active compound prepared by the preparation method or the use of the Lachnospira active compound in the preparation of tyrosinase inhibitors and α-glucosidase inhibitors.
[0028] The present invention also provides the active compound of Lachnospira spp. prepared by the preparation method or the application of the active compound of Lachnospira spp. in the preparation of skin care products and blood sugar-lowering drugs.
[0029] The present invention also provides a hypoglycemic pharmaceutical composition, which uses the Lachnospira active compound prepared by the preparation method or the Lachnospira active compound or a pharmaceutically acceptable salt thereof as an effective ingredient.
[0030] The hypoglycemic pharmaceutical composition provided by the present invention may also contain other hypoglycemic drugs; and may also contain pharmaceutically acceptable excipients (preferably pharmaceutically acceptable carriers, diluents or excipients). The dosage form of the pharmaceutical composition may be a solid preparation, a semisolid preparation or a liquid preparation.
[0031] The "pharmaceutically acceptable salt" in the present invention refers to a non-toxic addition salt of an inorganic or organic acid and / or base.
[0032] Compared with the prior art, the present invention has the following advantages and technical effects:
[0033] The present invention provides an active compound of Lachnophora spp. and a preparation method and application thereof. The whole Lachnophora spp. is dried, crushed, soaked in anhydrous ethanol, and concentrated under reduced pressure to obtain an extract. The ethanol extract is dispersed, extracted with petroleum ether to obtain a petroleum ether extract, and the remaining water layer is extracted with ethyl acetate to obtain an ethyl acetate extract. The extract is eluted to obtain the active compound. The chemical components in the Lachnophora spp. of the present invention are used to prepare skin care products and hypoglycemic drugs with whitening and antioxidant effects. The inhibitory effects on tyrosinase activity and ABTS + The free radical scavenging effect and the inhibitory effect of α-glucosidase activity are also good. The present invention solves the technical problems of the carcinogenic risk of existing whitening substances and the easy discoloration caused by environmental influences, thereby affecting the whitening effect, as well as the problems of gastrointestinal bloating, diarrhea, and polysaccharide decomposition and absorption disorders in the small intestine in existing hypoglycemic drugs, and provides a simple extraction method to extract the active compounds of Lachnophora sphaerocephala with good whitening, antioxidant and hypoglycemic effects.
[0034] The technical solution of the present invention is further described in detail below through embodiments. DETAILED DESCRIPTION
[0035] The technical solution of the present invention is further illustrated by the following embodiments.
[0036] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.
[0037] Sources of materials used in the present invention: Unless otherwise specified, the equipment and methods used in the present invention are commonly used equipment and methods in the technical field. The raw materials used are all conventional commercial products in the field.
[0038] Example 1 This example provides an active compound of Lachnophora sphaerocephala
[0039] S1. Naturally air-dry and crush 500 g of the Herba Lycopodii to obtain powder;
[0040] S2, the volume ratio of anhydrous ethanol to powder is 1:1, soak 3 times, each time for 7 days, the temperature is 37 ° C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, the condensed water temperature is 5 ° C, and the reduced pressure concentration is obtained to obtain 13.80 g of ethanol extract;
[0041] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0042] S4, ethyl acetate extract was separated on a 300-400 mesh silica gel chromatography column, and petroleum ether-ethyl acetate mobile phase was used for gradient elution at a volume ratio of 5:1 and 1:1 (the following mobile phase ratios are all volume ratios), to obtain 11 components (Fr.E1-Fr.E11).
[0043] The component Fr.E5 was separated on a 300-400 mesh silica gel column, and the petroleum ether-ethyl acetate mobile phase was eluted at a gradient of 3:1 and 1:1 to obtain three sub-components Fr.E5A-Fr.E5C. The component Fr.E5C was separated on a 300-400 mesh silica gel column, and the petroleum ether-ethyl acetate mobile phase was eluted at a ratio of 4:1 to obtain three sub-components Fr.E5C1-Fr.E5C3. The sub-component Fr.E5C3 was chromatographed on a Sephadex LH-20 gel column, and the petroleum ether-dichloromethane-methanol mobile phase was eluted at a ratio of 2:1:1 to obtain two sub-components Fr.E5C3A-Fr.E5C3B. The sub-component Fr.E5C3B was separated on a 300-400 mesh silica gel column, and the dichloromethane-methanol mobile phase was eluted at a ratio of 80:1 to obtain the active compound 1, the structural formula of which is as follows:
[0044]
[0045] Example 2 This example provides an active compound of Lachnophora sphaerocephala
[0046] S1. Naturally air-dry and crush 500 g of the Herba Lycopodii to obtain powder;
[0047] S2, the volume ratio of anhydrous ethanol to powder is 1:1, soak 3 times, each time for 7 days, the temperature is 37 ° C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, the condensed water temperature is 5 ° C, and the reduced pressure concentration is obtained to obtain 13.80 g of ethanol extract;
[0048] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0049] S4. The petroleum ether extract was chromatographed on a 300-400 mesh silica gel column using a petroleum ether-ethyl acetate mobile phase with a gradient elution ratio of 50:1, 20:1, 10:1, and 1:1 to obtain 11 components (Fr.P1-Fr.P11).
[0050] Component Fr.P7 was chromatographed on a Sephadex LH-20 gel column, eluted with a petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1, and obtained two subcomponents Fr.P7A-Fr.P7B. Subcomponent Fr.P7B was chromatographed on a 300-400 mesh silica gel column, eluted with a dichloromethane-methanol mobile phase at a ratio of 300:1, and obtained five subcomponents Fr.P7B1-Fr.P7B5. Subcomponent Fr.P7B2 was chromatographed on a 300-400 mesh silica gel column, eluted with a dichloromethane-methanol mobile phase at a ratio of 800:1, and obtained active compound 2, the structural formula of which is as follows:
[0051]
[0052] Example 3 This example provides an active compound of Lachnophora sphaerocephala
[0053] S1. Naturally air-dry and crush 500 g of the Herba Lycopodii to obtain powder;
[0054] S2, the volume ratio of anhydrous ethanol to powder is 1:1, soak 3 times, each time for 7 days, the temperature is 37 ° C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, the condensed water temperature is 5 ° C, and the reduced pressure concentration is obtained to obtain 13.80 g of ethanol extract;
[0055] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0056] S4 and ethyl acetate extract were separated on a 300-400 mesh silica gel chromatography column and eluted with petroleum ether-ethyl acetate mobile phase at a gradient of 5:1 and 1:1 to obtain 11 components (Fr.E1-Fr.E11).
[0057] Component Fr.E4 was separated on a 300-400 mesh silica gel column and eluted with dichloromethane-methanol mobile phase at a ratio of 150:1 to obtain two sub-components Fr.E4A-Fr.E4B. Component Fr.E4B was chromatographed on a Sephadex LH-20 gel column and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain active compound 3, the structural formula of which is as follows:
[0058]
[0059] Example 4 This example provides an active compound of Lachnophora sphaerocephala
[0060] S1. Naturally air-dry and crush 500 g of the Herba Lycopodii to obtain powder;
[0061] S2, the volume ratio of anhydrous ethanol to powder is 1:1, soak 3 times, each time for 7 days, the temperature is 37 ° C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, the condensed water temperature is 5 ° C, and the reduced pressure concentration is obtained to obtain 13.80 g of ethanol extract;
[0062] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0063] S4. The petroleum ether extract was chromatographed on a 300-400 mesh silica gel column using a petroleum ether-ethyl acetate mobile phase with a gradient elution ratio of 50:1, 20:1, 10:1, and 1:1 to obtain 11 components (Fr.P1-Fr.P11).
[0064] Component Fr.P3 was separated on a 300-400 mesh silica gel column, and eluted with petroleum ether-ethyl acetate mobile phase at a ratio of 70:1 to obtain four subcomponents Fr.P3A-Fr.P3D. Subcomponent Fr.P3C was chromatographed on a Sephadex LH-20 gel column, and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain active compound 4, the structural formula of which is as follows:
[0065]
[0066] Example 5 This example provides an active compound of Lachnophora sphaerocephala
[0067] S1. Naturally air-dry and crush 500 g of the Herba Lycopodii to obtain powder;
[0068] S2, the volume ratio of anhydrous ethanol to powder is 1:1, soak 3 times, each time for 7 days, the temperature is 37 ° C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, the condensed water temperature is 5 ° C, and the reduced pressure concentration is obtained to obtain 13.80 g of ethanol extract;
[0069] S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract;
[0070] S4. The petroleum ether extract was chromatographed on a 300-400 mesh silica gel column using a petroleum ether-ethyl acetate mobile phase with a gradient elution ratio of 50:1, 20:1, 10:1, and 1:1 to obtain 11 components (Fr.P1-Fr.P11).
[0071] Component Fr.P5 was separated on a 300-400 mesh silica gel column, and eluted with petroleum ether-ethyl acetate mobile phase at a ratio of 25:1 to obtain five subcomponents Fr.P5A-Fr.P5E. Subcomponent Fr.P5D was chromatographed on a Sephadex LH-20 gel column, and eluted with petroleum ether-dichloromethane-methanol mobile phase at a ratio of 2:1:1 to obtain active compound 5, the structural formula of which is as follows:
[0072]
[0073] The effects of the active compounds 1-5 of the herba tricholoma provided in Examples 1-5 were verified by the following tests:
[0074] 1. Detection of the whitening effect of active compounds of Lachnophora scabra:
[0075] Preparation of L-tyrosine solution: Take 100.0 mg of dry L-tyrosine powder, add pH 6.8 phosphate buffer to dissolve it, transfer to a 100 mL brown volumetric flask, dilute to the mark, and obtain a 1.0 mg / mL L-tyrosine solution.
[0076] Preparation of tyrosinase solution: Take 2 mg of tyrosinase powder, add pH 6.8 phosphate buffer to dissolve it, transfer to a 100 mL brown volumetric flask, and dilute to the mark to obtain 100 U / mL.
[0077] Preparation of reference solution: Weigh 1.0 mg of vitamin C powder, add appropriate amount of anhydrous ethanol to dissolve, transfer to a 10 mL brown volumetric flask, dilute to the mark to obtain 1.0 mg / mL vitamin C stock solution, and store at room temperature for later use.
[0078] Sample solution to be tested: Prepare into 1.0 mg / mL solution and set aside.
[0079] The test sample solution and tyrosinase activity inhibition experimental conditions are shown in Table 1. A 96-well plate was used, 25 μL of sample solution and 25 μL of tyrosinase solution were added, and then 100 μL of L-tyrosine solution was added to initiate the reaction. The plate was placed in an ELISA instrument and incubated at 37°C for 30 minutes with shaking, and scanned and detected at a wavelength of 475 nm, and the data was recorded. The absorbance of different extract samples was measured, with vitamin C as the positive control. Three plate wells were set for each group, and the average value was taken. The inhibition rate calculation formula is as follows: Inhibition rate (%) = [1-(A1-A2) / (A3-A0)] × 100%
[0080] In the formula: A1: sample group; A2: sample group control group; A3: blank group; A0: blank control group.
[0081] IC inhibition of tyrosinase activity by chemical components of Lachnophora sphaerocephala 50 The values are shown in Table 2.
[0082] Table 1 Tyrosinase activity inhibition test reaction system
[0083] Reaction system PBS solution Sample solution Tyrosinase Solution L-Tyrosine Solution <![CDATA[A1]]> 50μL 25μL 25μL 100μL <![CDATA[A2]]> 75μL 25μL - 100μL <![CDATA[A3]]> 50μL 25μL 25μL 100μL <![CDATA[A0]]> 75μL 25μL - 100μL
[0084] The tyrosinase activity of the active compounds 1-5 of Lachnophora sphaerocephala provided in Examples 1-5 and vitamin C in the control group was tested by the above method. The results are shown in Table 2.
[0085] Table 2 Inhibition of tyrosinase by active compounds of Lachnophora sphaerocephala
[0086] Group <![CDATA[IC 50 (μM)]]> Example 1 43.86 Example 2 34.14 Example 3 5.42 Example 4 47.17 Example 5 <![CDATA[- 1 ]]> <![CDATA[Control group 2 > 5.68
[0087] Note: In the table, " 1 "In the initial screening experiment, when the concentration was 0.1 mg / mL, the inhibition rate was less than 50%, which was considered inactive; in the table, " 2 Vitamin C was used as a positive control.
[0088] As shown in Table 2, except for the compound provided in Example 5, the active compounds 1-4 provided in Examples 1-4 all have inhibitory effects on tyrosinase. Among them, the active compound 3 provided in Example 3 exhibits the strongest inhibitory activity, IC 50 The value is 5.42μM. Active compounds 1, 2, and 4 have moderate inhibitory activity, IC 50 The values were 43.86μM, 34.14μM, and 47.17μM, respectively. Structurally, active compound 3 differs from active compound 1 in the substituted hydroxyl group at C-19. The results show that this substitution can improve the biological activity of active compounds from Lachnophora sphaerocephala and has a high potential in the development of whitening products.
[0089] 2. Detection of the antioxidant effect of active compounds from Lachnophora spp.
[0090] ABTS + Solution: Weigh 38.4 mg ABTS, add appropriate amount of distilled water to dissolve, transfer to a 10 mL brown volumetric flask, dilute to the mark, and obtain 3.84 mg / mL ABTS + At the same time, weigh 6.7 mg of potassium persulfate powder, add an appropriate amount of distilled water to dissolve, transfer to a 10 mL brown volumetric flask, dilute to the mark, and obtain a 0.67 mg / mL potassium persulfate aqueous solution. Take equal volumes of the above two aqueous solutions, mix them, store at room temperature, and react for 12-16 hours to obtain ABTS + Reserve solution for future use.
[0091] Reference solution: Weigh 10.0 mg of vitamin C powder, add an appropriate amount of anhydrous ethanol to dissolve, transfer to a 10 mL brown volumetric flask, dilute to the scale to obtain a 1.0 mg / mL vitamin C stock solution, and store at room temperature for later use.
[0092] Sample solution to be tested: Prepare into 1.0 mg / mL solution and set aside.
[0093] ABTS + The reaction system of the free radical scavenging experiment is shown in Table 3. 30 μL of sample solution and 170 μL of ABTS were added to a 96-well plate. + The solution was placed in an ELISA instrument and incubated at 37°C for 30 minutes, and the absorbance of the reaction was measured at 734 nm. Vitamin C standard was used as a positive control, and each group of samples was repeated three times in parallel. SPSS was used for data analysis to calculate the IC value of each sample to be tested. 50value.
[0094] Table 3 ABTS + Reaction system for free radical scavenging experiments
[0095] Reaction system Sample solution <![CDATA[ABTS + Solution]]> <![CDATA[A1]]> 30μL 170μL <![CDATA[A2]]> 30μL 170μL <![CDATA[A0]]> 30μL 170μL
[0096] Effect of active compounds of Lachnophora sphaerocephala on ABTS + The calculation formula of free radical scavenging rate (%) is as follows:
[0097] Clearance rate (%) = [1-(A1-A2) / A0] × 100%
[0098] Wherein: A1: sample group; A2: control group; A0: blank group.
[0099] By ABTS + The antioxidant activity of the active compounds of Lachnophora sphaerocephala and vitamin C in the positive control group were tested by the method, and the results are shown in Table 4.
[0100] Table 4 ABTS + Results of free radical scavenging compound bioassays
[0101] Group <![CDATA[IC 50 (μM)]]> Example 1 <![CDATA[- 1 ]]> Example 2 <![CDATA[- 1 ]]> Example 3 <![CDATA[- 1 <!-- 7 -->]]> Example 4 4.23 Example 5 2.03 <![CDATA[Control group 2 > 0.11
[0102] Note: In the table, " 1 "In the initial screening test, when the concentration was 1 mg / mL, the free radical scavenging rate was less than 50%, which was considered inactive; in the table, " 2 Vitamin C was used as a positive control.
[0103] As shown in Table 4, the active compounds 4 and 5 of Lachnophora sphaerocephala provided in Examples 4 and 5 have significant antioxidant activity, IC 50 The values were 4.23mM and 2.03mM respectively, and the positive control vitamin C (IC 50 =0.11 mM). Based on the structure-activity relationship analysis between 4 and 5, the hydroxylation at C-20 and the acetylation at C-3 enhanced their antioxidant activity.
[0104] 3. Detection of α-glucosidase activity of active compounds from Lachnophora spp.
[0105] α-Glucosidase solution: Weigh 3.0 mg of α-glucosidase powder, dissolve it with pH 6.8 phosphate buffer, transfer it to a 250 mL brown volumetric flask, dilute to the mark to obtain 1.0 U / mL α-glucosidase stock solution, and store it at -20°C for later use.
[0106] PNPG solution: Weigh 37.6 mg of PNPG powder, dissolve it in phosphate buffer with a pH of 6.8, transfer it to a 50 mL brown volumetric flask, and dilute to the mark to obtain a 5.0 mmol / LP PNPG solution.
[0107] Na2CO3 solution: Weigh 1.0600 g of anhydrous sodium carbonate powder, dissolve it in phosphate buffer with a pH of 6.8, transfer it to a 50 mL brown volumetric flask, and dilute to the mark to obtain a 0.2 mol / L Na2CO3 solution.
[0108] Reference solution: Weigh 1.0 mg of acarbose powder, dissolve it in anhydrous ethanol, transfer it to a 10 mL brown volumetric flask, and dilute to the mark to obtain a 0.1 mg / mL acarbose stock solution.
[0109] Sample solution to be tested: Prepare into 1.0 mg / mL solution and set aside.
[0110] The reaction system of the α-glucosidase activity inhibition experiment is shown in Table 5. Add 20 μL of sample solution and 50 μL of α-glucosidase solution to a 96-well plate and place it in a microplate reader for shaking and incubation at 37°C for 15 minutes. Add 50 μL of PNPG solution and continue shaking and incubating at 37°C for 15 minutes. Then add 100 μL of Na2CO3 solution to terminate the reaction, and measure the reaction absorbance at 405 nm. Using acarbose standard as a positive control, each group of samples was repeated three times in parallel to calculate the IC of each sample to be tested. 50 value.
[0111] Table 5 Reaction system of α-glucosidase activity inhibition test
[0112]
[0113] The calculation formula of α-glucosidase inhibition rate is as follows:
[0114] Inhibition rate (%) = [1-(A1-A2) / (A3-A0)] × 100%
[0115] Wherein: A1: sample group; A2: sample control group; A3: blank group; A0: blank control group.
[0116] The α-glucosidase inhibitory activity of the active compounds of Lachnophora sphaerocephala and the positive control group acarbose was tested by the PNPG method. The results are shown in Table 6.
[0117] Table 6 α-glucosidase inhibition bioassay results
[0118] Group <![CDATA[IC 50 (μM)]]> Example 1 _1 Example 2 0.89 Example 3 _1 Example 4 _1 Example 5 0.72 <![CDATA[Control group 2 > 0.0080
[0119] 1In the initial screening experiment, when the concentration was 1 mg / mL, the inhibition rate was less than 50% and was considered inactive.
[0120] 2 Acarbose was used as a positive control.
[0121] As shown in Table 6, active compounds 2 and 5 of Lachnophora sphaerocephala had moderate inhibitory effects on α-glucosidase, with IC 50 The values were 0.89 mM and 0.72 mM, respectively. However, Examples 1, 3 and 4 were inactive in the biological test. Combining the experimental results with the structural differences of the compounds, it is speculated that the acetylation at C-3 or the hydroxylation at C-19 of the ursane-type triterpenes 1 and 3 led to the loss of inhibitory activity.
[0122] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing an active compound of Lachnophora sphaerocephala, It is characterized in that The steps include: S1. Naturally air-drying and crushing the Lachnos nux vomica sample to obtain powder; S2, soaking the powder obtained in step S1 in anhydrous ethanol, and concentrating under reduced pressure to obtain an ethanol extract; S3, dispersing the ethanol extract obtained in step S2, extracting it with petroleum ether to obtain a petroleum ether extract, and extracting the remaining water layer with ethyl acetate to obtain an ethyl acetate extract; S4. The petroleum ether extract or ethyl acetate extract obtained in step S3 is separated on a 300-400 mesh silica gel chromatography column and eluted with a petroleum ether-ethyl acetate mobile phase to obtain multiple components, which are further separated and purified to obtain active compounds through an elution procedure.
2. The preparation method according to claim 1, It is characterized in that The volume ratio of anhydrous ethanol to powder in step S2 is 1:1, and the soaking is performed 3 times, each time for 7 days.
3. The preparation method according to claim 1, It is characterized in that In step S2, the temperature of reduced pressure concentration is 37°C, the vacuum degree is 0.1 MPa, the rotation speed is 70 rpm / min, and the condensed water temperature is 5°C.
4. The preparation method according to claim 1, It is characterized in that In step S4, the chromatography column used in the separation and purification is one or both of a 300-400 mesh silica gel chromatography column or a Sephadex LH-20 gel column chromatography column.
5. The preparation method according to claim 1, It is characterized in that Step S4, in the elution procedure, the mobile phase is one or more of petroleum ether-ethyl acetate, dichloromethane-methanol, and petroleum ether-dichloromethane-methanol.
6. The Lachnospira active compound prepared by the method for preparing the Lachnospira active compound according to any one of claims 1 to 5.
7. The active compound of Lachnophora sphaerocephala according to claim 6, It is characterized in that The structure of the compound includes:
8. Use of the active compound of Lachnospira spp. prepared by the preparation method according to any one of claims 1 to 5 or the active compound of Lachnospira spp. according to claim 6 in the preparation of tyrosinase inhibitors and α-glucosidase inhibitors.
9. Use of the active compound of Lachnospira spp. prepared by the preparation method according to any one of claims 1 to 5 or the active compound of Lachnospira spp. according to claim 6 in the preparation of skin care products and hypoglycemic drugs.
10. A hypoglycemic pharmaceutical composition, It is characterized in that The active compound of Lachnospira spp. prepared by the preparation method according to any one of claims 1 to 5 or the active compound of Lachnospira spp. according to claim 6 or a pharmaceutically acceptable salt thereof is used as the active ingredient.
Citation Information
Cited By
Angelica keiskei peptide hypoglycemic pill with hypoglycemic activity
CN120550073A
